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Abstract: This study was performed to investigate the expression of reactive oxygen species (ROS)-related proteins 
and to analyze the implications for primary and metastatic breast cancer. We constructed a tissue microarray con-
taining 143 metastatic breast cancers (52 lung metastases, 38 bone metastases, 37 brain metastases, and 16 
liver metastases) and performed immunohistochemical staining for ROS-related proteins (catalase, GSTπ, TxNIP, 
and MnSOD). Analysis of ROS-related protein expression in metastatic breast cancers according to the metastatic 
sites revealed site-specific expression patterns. The expression of tumoral catalase was lower in bone metastases 
(P = 0.012), and stromal GSTπ expression was higher in bone and liver metastases (P < 0.001). The highest ROS ac-
tivation status was observed for lung metastases, while non-activated ROS was observed for bone metastases (P = 
0.001). Primary cancers were positive for stromal GSTπ, but a subset of lung metastases were negative (P = 0.021). 
Univariate analysis revealed that shorter overall survival (OS) was associated with negative catalase expression of 
the tumor (P = 0.026). Furthermore, univariate analyses according to the metastatic sites revealed that shorter OS 
was associated with TxNIP-positive tumors (P = 0.032) and the expression of stromal catalase (P = 0.032) in brain 
metastases. Tumors that were negative for MnSOD expression (P < 0.001) but positive for stromal catalase expres-
sion (P = 0.022) were associated with shorter OS in patients with liver metastases. In conclusion, cancer cells and 
stromal tissues showed different ROS-related protein expression patterns according to the metastatic site. In addi-
tion, the expression of ROS-related proteins is associated with patient prognosis. 
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Introduction 
Among all cancers, breast cancer has one of 
the highest rates of morbidity and mortality 
due to the occurrence of distant metastases. 
The major organs affected in metastatic breast 
cancer are the lung, brain, liver, and bone [1, 2]. 
However, most of the existing studies are per-
formed for metastases to the brain and bone 
[3-8]. Not all cancers show similar metastatic 
patterns, raising the seed and soil hypothesis, 
which states that a specific tumor (the seed) 
grows in a specific visceral organ (the soil) [9]. 
Metastatic breast cancer also displays specific 
characteristics depending on the metastatic 
site. According to previous studies, the charac-
teristics associated with brain metastases 
include young age, estrogen receptor (ER) neg-
ativity, prior lung metastasis, human epidermal 
growth factor receptor 2 (HER-2) overexpres-
sion, epidermal growth factor receptor (EGFR) 
overexpression, and basal subtype [5-7]. In 
contrast, the characteristics associated with 
bone metastases are lower histologic grade, ER 
positivity, ER positivity/progesterone receptor 
(PR) negativity, strand growth pattern, and the 
presence of fibrotic foci in invasive ductal carci-
noma [4, 10, 11]. Therefore, the fact that differ-
ent metastatic cancers display different char-
acteristics depending on the metastatic site is 
well supported. 
Neoplastic cells differ from normal cells; the 
most significant difference is that they receive 
constant stimulation from growth promoting 
signals. The resulting infinite cell proliferation 
allows for different metabolic activities of the 
neoplastic cells compared to the normal cells. 
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Specifically, these changes lead to accelerated 
cell proliferation and impose increased oxida-
tive stress, which results in an alteration of the 
normal redox balance.
A previous study showed that the redox buffer-
ing systems such as the thioredoxin, glutathi-
one, and antioxidant systems (for example cat-
alase and superoxide dismutase) are either 
deregulated or overexpressed in tumors [12-
14]. The altered redox process can lead to 
oncogenic transformation or mutations within 
the tumor. Consequently, the ROS pathway was 
recently investigated as a new possible target 
for therapy [15]. Because targeted therapy can 
be utilized not only for primary cancer but also 
for metastatic cancer, it is important to under-
stand the ROS status of both primary and met-
astatic cancers. It has previously been shown 
that the ER, PR, and HER-2 status of primary 
and metastatic breast cancers can be discor-
dant. Therefore, the relationship between the 
ROS status of primary and metastatic breast 
cancers needs to be investigated. To address 
this discrepancy, this study investigates the 
expression of ROS-related proteins and its 
implications in primary and metastatic breast 
cancers.
Materials and methods
Patient selection
Patients with invasive primary breast cancer 
and metastases to distant organs (lung, bone, 
brain, and liver) were selected using their medi-
cal records at the Department of Pathology of 
Severance Hospital. Only patients with a diag-
nosis of invasive ductal carcinoma were includ-
ed. In total, 143 patients were identified, and 
for 38 of those patients samples of primary and 
metastatic cancers were available. All slides 
were reviewed and the resulting pathologic 
diagnoses were approved by 2 pathologists 
in this study are shown in Table 1. Formalin-
fixed, paraffin-embedded (FFPE) tissue sam-
ples were used as follows: 3 μm-thick slices 
from the FFPE tissue block were deparaffinized 
and rehydrated in xylene and alcohol solutions 
and stained using the Ventana Discovery XT 
automated stainer (Ventana Medical System, 
Tucson, AZ, USA). Antigen retrieval was per-
formed with Cell Conditioning 1 buffer (citrate 
buffer pH 6.0, Ventana Medical Systems). 
Appropriate positive and negative controls were 
used. 
Interpretation of immunohistochemical results
A cut-off value of 1% or more was used to define 
ER and androgen receptor positivity in positive-
ly stained nuclei [17]. The HER-2 staining was 
analyzed according to the American Society of 
Clinical Oncology/College of American Path- 
ologists guidelines using the following catego-
ries: (0) = no immunostaining; (1+) = weak and/
or incomplete membrane staining in less than 
10% of tumor cells; (2+) = complete membrane 
staining that is either uniform or weak in at 
least 10% of tumor cells; and (3+) = uniform, 
intense membrane staining in at least 30% of 
tumor cells [18]. The HER-2 immunostaining 
was considered positive when a strong (3+) 
membrane staining was observed, whereas it 
was considered negative when none or weak (0 
to 1+) staining was seen.
IHC result interpretation was based on the 
product of the proportion of stained cells and 
the immunohistochemical staining intensity. A 
product between 0 and 1 was regarded as neg-
ative, a product between 2 and 4 as a low posi-
tive, and a product between 5 and 6 as a high 
positive [19]. The proportion of stained cells 
was scored as 0 for negative, 1 for positive with 
less than 30% of the cells stained, and 2 for 
positive with greater than or equal to 30% of 
cells stained. The staining intensity was scored 
Table 1. Clone, dilution, and source of antibodies used
Antibody Clone Dilution Source
Catalase Polyclonal 1:600 Abcam, Cambridge, UK
GSTπ Polyclonal 1:500 Assay Design, Michican, USA
TxNIP JY2 1:100 MBL International Corporation, Woburn, USA
MnSOD Polyclonal 1:100 Abcam, Cambridge, UK
GSTπ, Glutathione S-transferase π; TxNIP, Thioredoxin interacting protein; MnSOD, 
Manganese superoxide dismutase.
(JSK and WHJ). The histolog-
ical grade was assessed 
based on the Nottingham 
grading system [16]. This 
study was approved by the 
Institutional Review Board.
Immunohistochemistry 
The antibodies used for 
immunohistochemistry (IHC) 
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as 0 for negative, 1 for weak, 2 for moderate, 
and 3 for strong. 
Statistical analysis
Data were statistically processed using SPSS 
for Windows, version 12.0 (SPSS Inc., Chicago, 
IL, USA). Correlation analysis of the immunos-
taining results between primary and metastatic 
breast cancer was performed using the 
McNemar test. Comparative statistics were 
performed using chi-square analysis. Statistical 
significance was assumed for P < 0.05. Kaplan-
Meier survival curves and log-rank statistics 
were used to evaluate the time until tumor 
metastasis and the time of survival.
Results 
Basal characteristics of patients 
Our study included a total of 143 patients. Of 
these, 52 (36.4%) had lung metastases, 38 
(26.6%) had bone metastases, 37 (25.9%) had 
brain metastases, and 16 (11.2%) had liver 
metastases. The proportion of patients that 
were ER-positive and PR-positive was higher 
among those with bone and liver metastases 
compared to patients with metastases to other 
sites (P < 0.001). The proportion of patients 
that were HER-2 positive was higher in patients 
with brain metastases compared to patients 
with metastases to other sites (P = 0.035). 
Furthermore, luminal A type breast cancer was 
more common among patients with bone and 
liver metastases, while triple negative breast 
cancer (TNBC) was more common among 
patients with brain and lung metastases (P = 
0.010) (Table 2).
Expression of ROS-related proteins in breast 
cancer metastasis depending on the meta-
static site
The analysis of ROS-related protein expression 
depending on the metastatic site in metastatic 
breast cancer revealed site-specific expression 
patterns (Figure 1). The expression of catalase 
in tumor cells was lower in bone metastases (P 
= 0.012), and the expression of stromal gluta-
thione S-transferase π (GSTπ) was higher in 
bone and liver metastases (P < 0.001). The 
ROS status defined by the expression of ROS-
related proteins differed depending on the met-
Table 2. Basal clinicopathological characteristics of breast cancer metastases according to the meta-
static sites 
Parameters Total  n = 143 (%)
Bone metastasis
n = 38 (%)
Brain metastasis
n = 37 (%)
Liver metastasis
n = 16 (%)
Lung metastasis
n = 52 (%) P-value
Age (years) 0.169
    ≤ 50 75 (52.4) 22 (57.9) 17 (45.9) 5 (31.2) 31 (59.6)
    > 50 68 (47.6) 16 (42.1) 20 (54.1) 11 (68.8) 21 (40.4)
ER < 0.001
    Negative 66 (46.2) 7 (18.4) 26 (70.3) 4 (25.0) 29 (55.8)
    Positive 77 (53.8) 31 (81.6) 11 (29.7) 12 (75.0) 23 (44.2)
PR < 0.001
    Negative 100 (69.9) 21 (55.3) 36 (97.3) 7 (43.8) 36 (69.2)
    Positive 43 (30.1) 17 (44.7) 1 (2.7) 9 (56.2) 16 (30.8)
HER-2 0.035
    Negative 99 (69.2) 31 (81.6) 19 (51.4) 12 (75.0) 37 (71.2)
    Positive 44 (30.8) 7 (18.4) 18 (48.6) 4 (25.0) 15 (28.8)
Molecular subtypes < 0.001
    Luminal A 54 (37.8) 27 (71.1) 3 (8.1) 9 (56.2) 15 (28.8)
    Luminal B 24 (16.8) 5 (13.2) 8 (21.6) 3 (18.8) 8 (15.4)
    HER-2 29 (20.3) 4 (10.5) 12 (32.4) 3 (18.8) 10 (19.2)
    NBC 36 (25.2) 2 (5.3) 14 (37.8) 1 (6.2) 19 (36.5)
Patient death 48 (33.6) 21 (55.3) 11 (29.7) 4 (25.0) 12 (23.1) 0.010
ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; TNBC, triple negative breast 
cancer.
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astatic site; the highest ROS activation status 
was observed for lung metastases, while non-
activated ROS was observed in cancer cells 
derived from bone metastases (P = 0.001) 
(Table 3).
Correlation of expression of ROS-related pro-
teins between primary and metastatic breast 
cancer depending on the metastatic site
We analyzed the expression levels of ROS-
related proteins in primary and metastatic can-
cers in 38 patients from whom both samples 
were available, and found that the expression 
levels were not different. However, in metastat-
ic cancer patients, primary cancers were posi-
tive for stromal GSTπ, while a subset of lung 
metastases were negative (P = 0.021) (Table 
4).
The impact of autophagy-related protein ex-
pression on patient prognosis
Using univariate analysis, we analyzed the 
association of ROS-related protein expression 
with respect to patient prognosis (Table 5 and 
Figure 2). We found that the factor associated 
with shorter overall survival (OS) was a tumor 
with negative catalase expression (P = 0.026). 
Using univariate analysis with respect to the 
metastatic site, we found that the factors asso-
ciated with shorter OS in patients with brain 
metastases were tumors with positive Thiore- 
doxin Interacting Protein (TxNIP) staining (P = 
0.032) and stromal catalase expression (P = 
0.032). Tumors with negative manganese 
superoxide dismutase (MnSOD) staining (P < 
0.001) and positive stromal catalase expres-
Figure 1. Expression of ROS-related proteins in metastatic breast cancers according to the metastatic sites. The 
expression of tumoral catalase was lower in bone metastasis, and that of stromal GSTπ was higher in bone and liver 
metastasis.
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sion (P = 0.022) were associated with shorter 
OS in patients with liver metastases. 
Discussion
In this study, differences in the expression of 
ROS-related proteins were observed among 
patients with metastatic breast cancer depend-
ing on the metastatic site. Our analysis revealed 
site-specific expression patterns of catalase in 
tumor cells, with lower expression levels in 
patients with bone metastases (P = 0.012). 
Furthermore, higher expression levels of stro-
mal GSTπ were observed in patients with bone 
and liver metastases (P < 0.001). A comparison 
based on previous studies was not possible 
due to the lack of ROS-related protein expres-
sion data of metastatic breast cancers. ROS is 
widely known to play an important role in tumor 
metastasis [20]. ROS promotes metastasis by 
activating the signaling pathway that is involved 
in tumor metastasis. Mechanistically, ROS acti-
vates key signal transduction proteins through 
Table 3. Expression of ROS-related proteins in the tumor cell compartment of breast cancer metastasis 
according to the metastatic sites 
Parameters Totaln = 143 (%)
Bone metastasis
n = 38 (%)
Brain metastasis
n = 37 (%)
Liver metastasis
n = 16 (%)
Lung metastasis
n = 52 (%) P-value
Cancer cell compartment
    Catalase 0.012
        Negative 75 (52.4) 27 (71.1) 21 (56.8) 8 (50.0) 19 (52.4)
        Positive 68 (47.6) 11 (28.9) 16 (43.2) 8 (50.0) 68 (47.6)
    GSTπ 0.051
        Negative 102 (71.3) 31 (81.6) 28 (75.7) 13 (81.2) 30 (57.7)
        Positive 41 (28.7) 7 (18.4) 9 (24.3) 3 (18.8) 22 (42.3)
    TxNIP 0.126
        Negative 126 (88.1) 34 (89.5) 36 (97.3) 14 (87.5) 42 (80.8)
        Positive 17 (11.9) 4 (10.5) 1 (2.7) 2 (12.5) 10 (19.2)
    MnSOD 0.198
        Negative 5 (3.5) 1 (2.6) 3 (8.1) 1 (6.2) 0 (0.0)
        Positive 138 (96.5) 37 (97.4) 34 (91.9) 15 (93.8) 52 (100.0)
    ROS status 0.001
        Non-activated 113 (79.0) 35 (92.1) 32 (86.5) 14 (87.5) 32 (61.5)
        Activated 30 (21.0) 3 (7.9) 5 (13.5) 2 (12.5) 20 (38.5)
Stromal cell compartment
    Catalase 0.080
        Negative 130 (90.9) 31 (81.6) 36 (97.3) 14 (87.5) 49 (94.2)
        Positive 13 (9.1) 7 (18.4) 1 (2.7) 2 (12.5) 3 (5.8)
    GST π < 0.001
        Negative 99 (69.2) 21 (55.3) 32 (86.5) 4 (25.0) 42 (80.8)
        Positive 44 (30.8) 17 (44.7) 5 (13.5) 12 (75.0) 10 (19.2)
    TxNIP 0.623
        Negative 142 (99.3) 38 (100.0) 37 (100.0) 16 (100.0) 51 (98.1)
        Positive 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.9)
    MnSOD 0.110
        Negative 118 (82.5) 30 (78.9) 34 (91.9) 15 (93.8) 39 (75.0)
        Positive 25 (17.5) 8 (21.1) 3 (8.1) 1 (6.2) 13 (25.0)
    ROS status 0.426
        Non-activated 136 (95.1) 35 (92.1) 37 (100.0) 15 (93.8) 49 (94.2)
        Activated 7 (4.9) 3 (7.9) 0 (0.0) 1 (6.2) 3 (5.8)
GSTπ, Glutathione S-transferase π; TxNIP, Thioredoxin interacting protein; MnSOD, Manganese superoxide dismutase; ROS, Reac-
tive oxygen species.
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Table 4. Correlation of ROS-related protein expression in cancer cells between primary and metastatic 
breast cancers with respect to the metastatic sites
Parameters 
Total Bone metastasis Brain metastasis Liver metastasis Lung metastasis
n = 38 (%) P-value n = 7 (%) P-value n = 7 (%) P-value n = 3 (%) P-value n = 21 (%) P-value
Cancer cell compartment
    Catalase 0.118 1.000 0.500 1.000 0.453
        (+) → (+) 8 (21.1) 0 (0.0) 0 (0.0) 1 (33.3) 7 (33.3)
        (+) → (-) 5 (13.2) 2 (28.6) 0 (0.0) 0 (0.0) 3 (14.3)
        (-) → (+) 11 (28.9) 3 (42.9) 2 (28.6) 1 (33.3) 5 (23.8)
        (-) → (-) 14 (36.8) 2 (28.6) 5 (71.4) 1 (33.3) 6 (28.6)
    GSTπ 0.453 1.000 1.000 1.000 0.375
        (+) → (+) 2 (5.1) 0 (0.0) 0 (0.0) 0 (0.0) 2 (9.1)
        (+) → (-) 2 (5.1) 0 (0.0) 1 (14.3) 0 (0.0) 1 (4.5)
        (-) → (+) 5 (12.8) 1 (14.3) 0 (0.0) 0 (0.0) 4 (18.2)
        (-) → (-) 30 (76.9) 6 (85.7) 6 (85.7) 3 (100.0) 15 (68.2)
    TxNIP 1.000 1.000 1.000 1.000 1.000
        (+) → (+) 2 (5.1) 0 (0.0) 0 (0.0) 0 (0.0) 2 (9.1)
        (+) → (-) 3 (7.7) 1 (14.3) 0 (0.0) 0 (0.0) 2 (9.1)
        (-) → (+) 3 (7.7) 1 (14.3) 0 (0.0) 0 (0.0) 2 (9.1)
        (-) → (-) 31 (79.5) 5 (71.4) 7 (100.0) 3 (100.0) 16 (72.7)
    MnSOD 1.000 1.000 0.500 1.000 0.500
        (+) → (+) 34 (87.2) 6 (85.7) 5 (71.4) 3 (100.0) 20 (90.9)
        (+) → (-) 2 (5.1) 0 (0.0) 2 (28.6) 0 (0.0) 0 (0.0)
        (-) → (+) 3 (7.7) 1 (14.3) 0 (0.0) 0 (0.0) 2 (9.1)
        (-) → (-) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Stromal cell compartment
    Catalase 1.000 1.000 1.000 1.000 1.000
        (+) → (+) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
        (+) → (-) 5 (12.8) 1 (14.3) 1 (33.3) 1 (33.3) 2 (9.1)
        (-) → (+) 4 (10.3) 0 (0.0) 0 (0.0) 0 (0.0) 3 (13.6)
        (-) → (-) 30 (76.9) 6 (85.7) 2 (66.7) 2 (66.7) 17 (77.3)
    GSTπ 0.096 1.000 1.000 1.000 0.021
        (+) → (+) 5 (12.8) 0 (0.0) 0 (0.0) 1 (33.3) 4 (18.2)
        (+) → (-) 13 (33.3) 2 (28.6) 2 (28.6) 0 (0.0) 9 (40.9)
        (-) → (+) 5 (12.8) 2 (28.6) 1 (14.3) 1 (33.3) 1 (4.5)
        (-) → (-) 16 (41.0) 3 (42.9) 4 (57.1) 1 (33.3) 8 (36.4)
    TxNIP 1.000 1.000 1.000 1.000 1.000
        (+) → (+) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
        (+) → (-) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
        (-) → (+) 1 (2.6) 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.5)
        (-) → (-) 38 (97.4) 7 (100.0) 7 (100.0) 3 (100.0) 21 (95.5)
    MnSOD 1.000 1.000 1.000 1.000 0.688
        (+) → (+) 3 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 3 (13.6)
        (+) → (-) 5 (12.8) 1 (14.3) 2 (28.6) 0 (0.0) 2 (9.1)
        (-) → (+) 6 (15.4) 1 (14.3) 1 (14.3) 0 (0.0) 4 (18.2)
        (-) → (-) 25 (64.1) 5 (71.4) 4 (57.1) 3 (100.0) 13 (59.1)
GSTπ, Glutathione S-transferase π; TxNIP, Thioredoxin interacting protein; MnSOD, Manganese superoxide dismutase.
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Table 5. Univariate analysis of the impact of ROS-related protein expression in metastatic breast cancers on overall survival using the log-rank test
Parameters
Total n = 143 (%) Bone metastasis n = 38 (%) Brain metastasis n = 7 (%) Liver metastasis n = 16 (%) Lung metastasis n = 52 (%)
Mean survival
(95% CI) months P-value
Mean survival
(95% CI) months P-value
Mean survival
(95% CI) months P-value
Mean survival
(95% CI) months P-value
Mean survival
(95% CI) months P-value
Cancer cell compartment
    Catalase 0.026 0.940 0.390 0.940 0.139
        Negative 94 (75-114) 81 (57-105) 96 (64-128) 66 (47-84) 111 (68-153)
        Positive 120 (102-137) 60 (39-82) 87 (62-112) 85 (52-117) 124 (95-153)
    GSTπ 0.177 0.653 0.659 0.248 0.052
        Negative 116 (100-133) 87 (62-113) 105 (79-132) 91 (70-112) 144 (117-171)
        Positive 99 (72-126) 73 (29-116) 75 (39-111) 22 (13-31) 90 (35-145)
    TxNIP 0.383 0.467 0.032 n/a 0.061
        Negative 114 (99-129) 80 (58-102) 107 (84-130) n/a 146 (124-167)
        Positive 67 (48-85) 79 (73-85) 19 (19-19) n/a 66 (42-90)
    MnSOD 0.970 0.171 n/a <0.001 n/a
        Negative 126 (34-218) 165 (165-165) n/a 11 (11-11) n/a
        Positive 110 (96-125) 71 (56-86) n/a 92 (72-112) n/a
    ROS status 0.340 0.499 0.427 n/a 0.306
        Non-activated 108 (91-124) 80 (58-102) 99 (72-125) n/a 142 (117-167)
        Activated 88 (72-104) 79 (73-85) 98 (63-132) n/a 72 (55-90)
Stromal cell compartment
    Catalase 0.140 0.094 0.032 0.022 n/a
        Negative 112 (97-127) 87 (65-110) 107 (84-130) 91 (70-112) n/a
        Positive 91 (49-134) 37 (15-60) 19 (19-19) 21 (21-21) n/a
    GSTπ 0.551 0.317 0.824 n/a 0.215
        Negative 114 (97-131) 82 (65-100) 105 (81-128) n/a 126 (100-152)
        Positive 100 (74-126) 76 (37-116) 72 (29-115) n/a 130 (81-153)
    TxNIP n/a n/a n/a n/a n/a
        Negative n/a n/a n/a n/a n/a
        Positive n/a n/a n/a n/a n/a
    MnSOD 0.466 0.687 n/a n/a 0.968
        Negative 108 (92-123) 83 (60-106) n/a n/a 130 (103-158)
        Positive 120 (90-151) 50 (31-69) n/a n/a 123 (84-163)
    ROS status 0.716 0.264 n/a n/a n/a
        Non-activated 109 (94-124) 84 (62-105) n/a n/a n/a
        Activated 117 (62-173) 32 (0-65) n/a n/a n/a
GSTπ, Glutathione S-transferase π; TxNIP, Thioredoxin interacting protein; MnSOD, Manganese superoxide dismutase; ROS, Reactive oxygen species.
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Figure 2. The impact of autophagy-related proteins on patient prognosis in metastatic breast cancer (A), brain metastasis (B, C), and liver metastasis (D, E).
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oxidative posttranslational modifications of 
redox-sensitive proteins [21]. Therefore, meta-
static cancers are expected to show an increase 
in the expression of ROS-related proteins. In 
this study, the expression of ROS-related pro-
teins differed depending on the metastatic site. 
Previous studies reported different expression 
patterns of the most important biomarkers of 
breast cancer (ER, PR, and HER-2) according to 
the metastatic site. Most brain metastases are 
TNBC or HER-2 positive [6], whereas most bone 
metastases are hormone receptor positive [4]. 
These results were in agreement with our study. 
The proportion of hormone receptor positive 
cancer was high in liver metastases, and the 
proportion of TNBC was high in lung metasta-
ses. Our study showed different biological char-
acteristics depending on the metastatic site. 
Previous studies showed a reverse correlation 
between ER and ROS. Specifically, the suppres-
sion of ER resulted in increased ROS produc-
tion in breast cancer cells [22]. In this study, 
patients with bone metastases showed a high 
proportion of ER positivity and non-activated 
ROS status, while patients with lung metasta-
ses showed a low proportion of ER positivity 
and activated ROS status. Thus, the difference 
of ROS status according to the metastatic site 
could be the result of the hormone receptor 
status. Further research is required to substan-
tiate this hypothesis.
Stromal tissues showed different expression 
patterns of ROS-related proteins; stromal GSTπ 
showed higher expression levels in bone and 
liver metastases. The possible theory, which 
can explain the expression of ROS-related pro-
teins in stromal tissue, is the reverse-Warburg 
effect theory. According to this theory, cancer 
cells generate ROS (such as nitric oxide), which 
can cause oxidative stress and trigger glycoly-
sis, autophagy (mitophagy), and mitochondrial 
dysfunction through NFκB and HIF-1α in stro-
mal cells. Ketone bodies and lactate are formed 
through glycolysis in stromal cells that enter 
the cancer cells and produce ATP effectively 
through oxidative phosphorylation in the mito-
chondria of the cancer cells, which as a whole 
contributes to their survival and growth [23-
27]. According to the reverse Warburg effect 
theory, to maintain the metabolic support of 
cancer cells, stromal cells should withstand the 
oxidative stress caused by ROS secreted from 
cancer cells. If detoxifying enzymes such as 
GSTπ are expressed at high levels, stromal cells 
could maintain the metabolic support of cancer 
cells under such oxidative stress environments. 
Previous studies reported that the reverse 
Warburg effect occurs in a high proportion of 
hormone receptor-positive luminal type breast 
cancers [28]. In this study, bone and liver 
metastases, of which a high proportion was of 
the luminal type, showed high stromal GSTπ 
expression. This can be because most bone 
and liver metastases display a reverse Warburg 
effect. However, further validation is required 
to generalize the findings of this study.
The clinical significance of this study is that 
ROS regulators may be a treatment modality. 
Previous studies reported that the substance 
increasing ROS caused ROS-induced apoptosis 
in cancer cells, while normal cells were not 
affected [29, 30]. However, the substance 
decreasing ROS accelerated tumor growth [31]. 
Therefore, ROS modulators can be considered 
as potential therapeutic agents that cause can-
cer cell death by further increasing ROS levels 
in targeted metastatic cancers with already 
increased ROS levels. However, more research 
is required to validate this hypothesis.
In conclusion, our study showed different 
expression patterns of ROS-related proteins in 
cancer cells and stromal tissues in metastatic 
breast cancers depending on the metastatic 
site. The expression of catalase was lower in 
bone metastases and that of stromal GSTπ was 
higher in bone and liver metastases.
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